Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2011-01-11
2011-01-11
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S234100, C424S201100, C424S203100, C424S185100, C424S282100, C424S247100, C424S240100, C424S268100, C424S210100, C424S227100, C424S250100, C424S239100, C424S832000, C424S184100, C514S002600, C530S350000, C530S300000, C530S825000, C530S822000, C530S826000, C530S806000, C530S807000
Reexamination Certificate
active
07867498
ABSTRACT:
The invention relates to polypeptide carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines are particularly useful to confer protection against infection from encapsulated bacteria in infants between the ages of 3 months and about 2 years.
REFERENCES:
patent: 4695624 (1987-09-01), Marburg et al.
patent: 4870009 (1989-09-01), Evans et al.
patent: 4882317 (1989-11-01), Marburg et al.
patent: 4902506 (1990-02-01), Anderson et al.
patent: 5651971 (1997-07-01), Lees
patent: 5728385 (1998-03-01), Classen
patent: 6855321 (2005-02-01), Rappuoli et al.
patent: 2008/0260769 (2008-10-01), Capecchi et al.
patent: 0270295 (1988-06-01), None
patent: 0429816 (1991-06-01), None
patent: WO 86/05790 (1986-09-01), None
patent: WO 92/21374 (1992-10-01), None
patent: WO 96/03144 (1995-07-01), None
patent: WO 98/43677 (1998-08-01), None
patent: 2006/011060 (2006-02-01), None
Agadjanyan, et al., “Peptide mimicry of carbohydrate epitopes on human immunodeficiency virus,”Nature Biotechnol15:547-551 (1997).
Ahlers, et al., “Construction of an hiv-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations,”J Immunol150(12):5647-5665 (1993).
An, et al., “A multivalent minigen vaccine, containing B-cell, cytotoxic T-lymphocyte and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen,”J Virol71(3):2292-2302 (1997).
Andreoni, et al., “Vaccination and the role of capsular polysaccharide antibody in prevention of recurrent meningococcal disease in late complement component-deficient individuals,”J Infect Dis168:227-231 (1993).
Anderson, et al., “Antibody responses toHaemophilus influenzatype b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM,”Infect Immun39(1):233-238 (1983).
Anderson, et al., “Immunization of 2-month-old infants with protein-coupled oligosaccharides derived from the capsule ofHaemophilus influenzatype b,”J Pediatrics107:346-351 (1985).
Anderson, et al., “Immunogens consisting of oligosaccharides from the capsule ofHaemophilus influenzatype b coupled to diphtheria toxoid or the toxin protein CRM197,”J Clin Invest76:52-29 (1985).
Bixler, et al., “Synthetic peptide representing a T-cell epitope of CRM197 substitutes as carrier molecule in a Haemophilus influenza type b (HIB) conjugate vaccine,”Adv Exper Med Bio251:175-180 (1989).
Chang, et. al., “Anergy in immature b lymphocytes differntial responses to receptor-mediated stimulation and T helper cells,” J Immun 147(3):750-756 (1991).
Christodoulides, et al., “Immunization with a multiple antigen peptide containing defined B- and T-cell epitopes: production of bacteriocidal antibodies against group B neisseria meningitides,”Microbiology140(11):2951-2960 (1994).
Constantino, et al., “Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and C,”Vaccine10(10):691-698 (1992).
De Velasco, et al., “Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines,”Inf Immun63(3):961-968 (1995).
Dick, et al., “Glycoconjugates of bacterial carbohydrate antigens,”Conjugate vaccines10:48-114 (1989).
Etlinger, et al., “Use of prior vaccinations for the development of new vaccines,”Science249:423-425 (1990).
Falugi, et al., “Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines,”Eur J Immunol31:3816-3824 (2001).
Goldblatt, et al., “Role of cell wall polysaccharide in the assessment of IgG antibodies to the capsular polysaccharides of streptococcus pneumoniae in childhood,”J Inf Dis166:632-634 (1992).
Good, et al., “Construction of synthetic immunogen: use of new T-helper epitope on malaria circumsporozite protein,”Science235:1059-1062 (1987).
Grandoff, et al., “Effect of immunity to the carrier protein on antibody responses toHaemophilus influenzatype b conjugate vaccines,”Vaccine11(1):546-551 (1993).
Grandoff, et al., “Introduction of immunologic memory in infants primed withHaemophilus influenzatype b conjugate vaccines,”J Infect Dis168:663-671 (1993).
Hayward, et al., “Induction of plasma cell differentiation of human fetal lymphocytes: evidence for functional immaturity of t and b cells,”J Immun119(4):1213-1217 (1977).
Holmes, et al., “The biology ofHaemophilus influenzatype b vaccination failure,”J Infect Dis165:5121-5128 (1992).
Insel, et al., “Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgC antibody responses to theHaemophilus influenzab capsular polysaccharide in human infants,”J Exp Med163:262-269 (1986).
Ishioka, et al., “MHC interaction and T cell recognition of carbohydrates and glycopeptides,”J Immun148:2446-2451 (1992).
Houdebine, “Transgenic animal bioreactors,”Transgenic Research9:305-320 (2000).
Jennings, et al., “Immunochemistry of groups A, B, and C meningococcal polysaccharide-tetanus toxoid conjugates,”J Immun127:1011-1018 (1981).
Jennings, et al., in “Seminars in infectious disease,” Weinstein, et al., Ed., vol. IV, Chapter 34, pp. 247-253 (1982).
Kaliyaperumal, et al., “Carrier-induced epitope-specific regulation and its bypass in a protein-protein conjugate,”Eur J Immunol25:3375-3380 (1995).
Kolb, et al., “Insertion of a foreign gene into the beta-casein locus by Cre-mediated site-specific recombination,”Gene227:21-31 (1999).
Konadu, et al., “Synthesis characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide ofSalmonella paratyphiA bound to tetanus toxoid with emphasis on the role ofOacetyls,”Infect Immun64(7):2709-2715 (1996).
Konen-Waisman, et al., “Self and foreign 60-kilodalton heat shock protein T cell epitope peptides serve as immunogenic carriers for a T cell-Independent sugar antigen,”J Immunol154:5977-5985 (1995).
Kumar, et al., “Universal T helper cell determinants enhance immunogenicity of aPlasmodium falciparummerozite surface antigen peptide,”J Immunol148:1499-1505 (1992).
Leclerc, et al., “A synthetic vaccine constructed by copolymerization of B and T cell determinants,”Eur L Immunol17:269-273 (1987).
Leiter, “Mice with targeted gene disruptions or gene insertions for diabetes research: problems, pitfalls, and potential solutions,”Diabetologia45:296-308 (2002).
Lett, et al., “Immunogenicity of polysaccharides conjugated to peptides containing T- and B-cell epitopes,”Infect Immun62(3):785-792 (1994).
Liptak, et al., “Decline of pediatric admissions withHaemophilus influenzatype b in New Yorl state, 1982 through 1993: Relation to immunizations,”J Pediatrics130:923-930 (1997).
Lucas, et al., “Functional Differences in idiotypically defined IgGI anti-polysaccharide antibodies elicited by vaccination withHaemophilus influenzatype b polysaccharide-protine conjugates,”J Immunol154:4195-4202 (1995).
McNamara, et al., “Monoclonal idiotope vaccine againstStreptococcus pneumoniaeInfection,”Science226:1325-1326 (1984).
Marburg, et al., “Bimolecular chemistry of macromolecules: synthesis of bacterial polysaccharide conjugates withNeisseria meningitidesmembrane protein,”J Am Chem108:5282-5287 (1986).
Moxon, et al., “The role of bacterial polysaccharide capsules as virulence f
Grandi Guido
Rappuoli Rino
Devi S.
Lee Helen
Littlefield Otis
Novartis AG
Robins Roberta
LandOfFree
Polypeptide carrier protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polypeptide carrier protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptide carrier protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2735636